Completed
A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
NCT02676895
- Conditions
- Shigella Sonnei Infection
- Locations
-
- GSK Investigational Site Kilifi, Kenya